10-Q: Immunic Faces Going Concern Doubt Amid Nasdaq Warning

Immunic, Inc. reported increased losses and a going concern warning, despite positive clinical trial data and recent capital raises, while also receiving a Nasdaq minimum bid price non-compliance notice.

Summary

• Immunic, Inc. incurred a net loss of $52.293 million for the six months ended June 30, 2025, compared to $50.964 million for the same period in 2024.
• Research and development expenses increased by $5.8 million (16%) to $42.902 million for the six months ended June 30, 2025, driven by vidofludimus calcium programs.
• General and administrative expenses rose by $1.4 million (14%) to $11.006 million for the six months ended June 30, 2025.
• Cash and cash equivalents stood at $55.310 million as of June 30, 2025, up from $35.668 million at December 31, 2024, primarily due to financing activities.
• The company has an accumulated deficit of approximately $563.7 million as of June 30, 2025.
• Immunic received a Nasdaq notice on June 27, 2025, for non-compliance with the $1.00 minimum bid price rule, with a compliance period until December 24, 2025.
• Phase 3 ENSURE trials for vidofludimus calcium in Relapsing Multiple Sclerosis (RMS) completed enrollment on June 5, 2025, with top-line data expected by the end of 2026.
• Positive clinical data from the Phase 2 CALLIPER trial of vidofludimus calcium in Progressive Multiple Sclerosis (PMS) showed a 20% reduction in 24-week confirmed disability worsening (30% in PPMS, 15% in naSPMS) and a 20% reduction in annualized thalamic brain volume loss.
• Long-term open-label extension data from the Phase 2 EMPhASIS trial in RRMS showed 92.3% of patients remained free of 12-week CDW and 92.7% free of 24-week CDW at week 144, with no new safety signals up to 5.5 years.
• IMU-856 demonstrated a dose-dependent increase of GLP-1 levels in a Phase 1b celiac disease trial and showed potential for weight management in preclinical testing.
• The company raised approximately $4.7 million net from the April 2025 Offering and $60.661 million net from the May 2025 Equity Offering, which included pre-funded and Series A/B warrants.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the explicit 'going concern' warning, increased net losses, and the Nasdaq non-compliance notice, which collectively indicate significant financial distress and operational risk. While there are positive clinical trial updates, these are overshadowed by the severe financial challenges and the immediate threat of delisting.

Positives

• Completion of enrollment for both Phase 3 ENSURE trials (RMS) on June 5, 2025, a significant milestone towards potential regulatory approval.
• Positive clinical data from the Phase 2 CALLIPER trial (PMS) for vidofludimus calcium, showing medically relevant reductions in disability progression (20% overall, 30% in PPMS) and brain volume loss (20%), reinforcing its neuroprotective potential.
• New long-term open-label extension data from the Phase 2 EMPhASIS trial (RRMS) demonstrated sustained efficacy with 92.3% of patients free of 12-week CDW at week 144 and a favorable safety profile over 5.5 years.
• IMU-856 showed a dose-dependent increase of GLP-1 levels in a Phase 1b trial and preclinical evidence of weight management potential, opening new therapeutic avenues.
• Successful capital raises in April and May 2025, generating approximately $65.5 million in net proceeds, significantly bolstering the cash position to $55.310 million as of June 30, 2025.

Negatives

• The company explicitly states 'substantial doubt about the Company’s ability to continue as a going concern' due to inadequate liquidity to fund operations for at least twelve months without raising additional capital.
• Net loss increased to $52.293 million for the six months ended June 30, 2025, from $50.964 million in the prior year period.
• Operating expenses increased by 15% to $53.908 million for the six months ended June 30, 2025, indicating a higher cash burn rate.
• Received a Nasdaq Listing Rule 5450(a)(1) non-compliance notice on June 27, 2025, due to the common stock closing bid price falling below $1.00 for 30 consecutive business days, posing a delisting risk.
• Conditions for the second and third tranches of the January 2024 Financing, which could provide up to an additional $160 million, have not been satisfied as of June 30, 2025.

Risks

• Failure to obtain additional capital could have a material adverse effect on operations, clinical development programs, and may lead to cessation of operations.
• Inability to regain compliance with Nasdaq's minimum bid price requirement by December 24, 2025, or subsequent periods, could result in delisting, negatively impacting share price, liquidity, and ability to raise capital.
• Clinical trials may fail to meet their endpoints, or product candidates may not obtain regulatory approval.
• Future expenses and capital requirements are difficult to forecast and depend on factors like the scope and progress of R&D, regulatory submissions, manufacturing, and commercialization activities.
• Raising additional capital through equity securities will dilute existing stockholders' ownership interest and may occur on unfavorable terms.
• Debt financing, if available, may involve restrictive covenants or unfavorable terms.
• Reliance on third-party collaborations and licensing arrangements may require relinquishing substantial rights to technologies or future products.
• The company has never been profitable and expects to incur significant and increasing operating losses for the foreseeable future.
• Exposure to foreign currency exchange rate fluctuations, primarily between the U.S. dollar and Euro, could adversely affect financial results, with a 10% adverse change potentially impacting net current liabilities by $1.4 million and net loss by $4.1 million for the six months ended June 30, 2025.

Future Outlook

The company expects to incur significant and increasing operating losses for the foreseeable future as it continues the development of its product candidates and expands its personnel. Top-line data for the Phase 3 ENSURE trials is anticipated by the end of 2026. Further clinical testing for IMU-856 is contingent on securing additional financing, licensing, or partnering. The company is exploring strategic options for its assets, including potential spin-offs and licensing transactions, and intends to continue leading R&D from its German and Australian operations for efficiency. The company will need substantial additional funding to meet long-term liquidity needs and continue operations, which it anticipates obtaining through indebtedness, additional equity financings, product licensing, or a combination thereof.

Management Comments

• "We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to advance our pipeline of product candidates."
• "With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these condensed consolidated financial statements included in this quarterly report without raising additional capital and such actions are not solely within the control of the Company."
• "If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company’s ability to continue as a going concern."
• "Although we currently believe that this goal [top-line data for ENSURE trials by end of 2026] is achievable, it is dependent on numerous factors, most of which are not under our direct control and can be difficult to predict."
• "If approved, we believe that vidofludimus calcium, with combined neuroprotective, anti-inflammatory, and antiviral effects as well as a favorable safety and tolerability profile, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS."
• "Based on preclinical investigations demonstrating no suppression of immune cells, IMU-856 may have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications and may allow the potential for combination with available treatments in gastroenterological diseases."
• "The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the minimum bid price requirement."

Industry Context

The biotechnology industry, particularly in drug development for chronic inflammatory and autoimmune diseases, is characterized by high research and development costs, long clinical trial timelines, and significant capital requirements. Immunic's focus on oral small molecule therapies for conditions like MS and celiac disease positions it in a competitive landscape with a high unmet medical need. The positive Phase 2 and OLE data for vidofludimus calcium and the emerging potential of IMU-856 for weight management indicate promising scientific progress. However, the industry also faces substantial financial risks, as evidenced by Immunic's going concern warning and Nasdaq compliance issues, which are common challenges for pre-revenue biotech companies reliant on external funding.

Comparison to Industry Standards

• The company's accumulated deficit of $563.7 million and consistent operating losses since inception are typical for a pre-revenue biotechnology company engaged in extensive clinical development, similar to early-stage companies like Biogen (BIIB) or Novartis (NVS) in their initial development phases for MS therapies, though Immunic is much smaller in scale and further from commercialization.
• The increase in R&D expenses by 16% to $42.9 million for the six months ended June 30, 2025, reflects continued investment in late-stage clinical programs, which is standard for companies advancing candidates into Phase 3, comparable to development costs seen in trials for drugs like Ocrevus (Roche) or Kesimpta (Novartis) in MS, albeit at a smaller absolute scale.
• The positive Phase 2 CALLIPER data for vidofludimus calcium, showing a 30% reduction in 24-week confirmed disability worsening in PPMS, is a clinically meaningful outcome. For context, Ocrevus, a leading MS drug, demonstrated a 24% reduction in confirmed disability progression in primary progressive MS patients in its Phase 3 ORATORIO trial, suggesting vidofludimus calcium's efficacy profile could be competitive if confirmed in Phase 3.
• The long-term safety and tolerability profile observed for vidofludimus calcium in the EMPhASIS OLE trial (up to 5.5 years) with low discontinuation rates and no new safety signals is a strong positive, as long-term safety is a critical factor for chronic disease treatments and a key differentiator in the MS market, where drugs like Tecfidera (Biogen) have faced safety concerns.
• The company's liquidity position, with cash and cash equivalents of $55.3 million, is precarious given the explicit 'going concern' warning, which is a more severe financial indicator than typically seen in well-capitalized biotech firms, even those in development stages. This situation is more akin to smaller, highly speculative biotechs that frequently need to raise capital to sustain operations, unlike larger players with established revenue streams.
• The Nasdaq minimum bid price non-compliance is a common issue for small-cap biotechs with declining stock prices, similar to challenges faced by companies like Sorrento Therapeutics (SRNE) or Athersys (ATHX) in the past, which can lead to delisting and further erode investor confidence and access to capital markets.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation, nor aware of any pending or threatened litigation, that is believed to materially affect business, operating results, financial condition, or cash flows.
• The industry is characterized by frequent claims and litigation, including securities litigation, intellectual property rights claims, and product liability claims, indicating potential future involvement in legal proceedings.

Related Party Transactions

• The Executive Chairman Agreement with Duane Nash, MD, JD, MBA, was extended via Addendum Number 6 on August 29, 2024, to December 31, 2025. His monthly base salary for 2025 was increased to $33,986 from $32,368.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent and potential future capital raises, including warrants. Are exposed to substantial doubt about the company's ability to continue as a going concern and the risk of Nasdaq delisting, which could severely impact share price and liquidity. However, positive clinical data for lead programs offers potential long-term value if financial challenges are overcome.
• **Employees**: Benefit from continued employment and potential for stock-based compensation, including the new Stock Appreciation Rights plan and the Corporate Transaction Option Acceleration Plan, which aim to incentivize and retain talent. However, the going concern warning and delisting risk could create uncertainty regarding job security and the value of equity awards.
• **Customers (Future)**: Potential future patients with MS, celiac disease, and other inflammatory/autoimmune conditions could benefit from the development of new oral therapies like vidofludimus calcium and IMU-856, offering new treatment options.
• **Creditors**: Face increased risk due to the company's 'going concern' warning and reliance on future capital raises to sustain operations.
• **Suppliers/CROs**: Continued engagement and increased R&D spending indicate ongoing business, but the company's liquidity concerns could pose payment risks if additional funding is not secured.

Next Steps

• Actively monitor the common stock's closing bid price and evaluate options to regain compliance with Nasdaq's minimum bid price requirement by December 24, 2025.
• Continue to fund ongoing clinical development of product candidates, including vidofludimus calcium, IMU-856, and IMU-381.
• Complete the analysis of the full data set from the Phase 2 CALLIPER clinical trial and discuss results with healthcare authorities to determine next steps for vidofludimus calcium in PMS.
• Prepare for additional clinical testing of IMU-856, contingent on securing financing, licensing, or partnering.
• Continue preclinical research to explore additional indications and generate new molecules.
• Facilitate readiness for potential commercial launch of product candidates, if regulatory approvals are received, through targeted pre-commercial activities.
• Evaluate potential strategic collaborations for each product candidate to complement R&D capabilities and facilitate commercialization.
• Seek stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to provide sufficient shares for the settlement of Stock Appreciation Rights (SARs) in common stock.

Key Dates

Recommendation

Despite promising clinical data for its pipeline, Immunic, Inc. faces severe financial distress, explicitly stating 'substantial doubt about the Company’s ability to continue as a going concern' and lacking adequate liquidity for the next twelve months. The Nasdaq non-compliance notice for minimum bid price further exacerbates the risk of delisting, which would significantly impair liquidity and investor confidence. While recent capital raises provide a temporary reprieve, they are highly dilutive, and the failure to meet conditions for additional tranches of the January 2024 financing highlights ongoing funding challenges. For a seasoned investor, the explicit going concern warning and immediate delisting threat outweigh the long-term potential of the clinical pipeline, making a 'sell' recommendation prudent to mitigate significant downside risk.

Keywords

Biotechnology, Clinical Trials, Multiple Sclerosis, Inflammatory Bowel Disease, Autoimmune Diseases, Drug Development, SEC Filing, Nasdaq Compliance, Capital Raise, Going Concern, IMU-838, IMU-856, IMU-381